{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:44:00Z","timestamp":1755794640202,"version":"3.44.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018446","name":"Alimera Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and\/or vitreoretinal surgery, which may spontaneously resolve. This study aimed to evaluate the effectiveness and safety of the fluocinolone acetonide intravitreal (FAc) implant (0.2\u00a0\u00b5g\/day) in patients with refractory PCME.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Retrospective, non-interventional, and single center study conducted on patients with PCME treated with 0.2\u00a0\u00b5g\/day FAc implant. All the patients received previous treatment with topical corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), triancinolone injection and dexamethasone implant. The primary end-points were the mean change in best-corrected-visual-acuity (BCVA) and the proportion of patients gaining\u2009\u2265\u200915 letters from baseline to the last follow-up visit. The secondary endpoints included the mean CRT reduction and the mean intraocular pressure (IOP) during the 36 months study period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eight eyes from 8 patients were included in the study. Median (95% Confidence-interval) BCVA was significantly improved from 60.0 (50.05\u201369.95) letters at baseline to 80.15 (77.25-85.00) letters at month-36, <jats:italic>p<\/jats:italic>\u2009=\u20090.043. At the last follow-up visit, 5 (62.5%) eyes gained\u2009\u2265\u200915 letters, without any eye experiencing a loss of BCVA compared to baseline. There was significant CRT reduction from baseline (median: 497.5\u00a0\u03bcm; 95%CI: 380.0\u2013596.0\u00a0\u03bcm) to month-36 (Median: 252.0\u00a0\u03bcm; 95%CI: 242.0\u2013268.0\u00a0\u03bcm); <jats:italic>p<\/jats:italic>\u2009=\u20090.012. Regarding safety, IOP remained stable from baseline (median: 14.5mmHg; 95%Confidence-interval: 12.0\u201323.0 mmHg) to the last follow-up visit (median: 13.5mmHg; 95% Confidence-interval: 9.0\u201319.0\u00a0mm Hg); <jats:italic>p<\/jats:italic>\u2009=\u20090.123.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The FAc implant significantly improved both visual and anatomic outcomes, and was effective in preventing recurrences, while maintaining a reasonable safety profile, in PCME refractory to intravitreal triancinolone and dexamethasone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12348-025-00503-8","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T01:43:38Z","timestamp":1755308618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 \u00b5g\/day) in patients with post-surgical inflammation associated with macular edema: a case series study"],"prefix":"10.1186","volume":"15","author":[{"given":"Maria","family":"Madeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Cabugueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Urbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"503_CR1","first-page":"232","volume":"64","author":"JD Gass","year":"1966","unstructured":"Gass JD (1966) Norton EW (1966) Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc 64:232\u201349","journal-title":"Trans Am Ophthalmol Soc"},{"key":"503_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/CIA.S111761","volume":"11","author":"A Grzybowski","year":"2016","unstructured":"Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V (2016) Pseudophakic cystoid macular edema: update 2016. Clin Interv Aging 11:1221\u20131229. https:\/\/doi.org\/10.2147\/CIA.S111761","journal-title":"Clin Interv Aging"},{"issue":"58","key":"503_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000455280","volume":"2017","author":"D Zur","year":"2017","unstructured":"Zur D, Loewenstein A (2017) Postsurgical Cystoid Macular Edema. Dev Ophthalmol. 2017(58):178\u2013190. https:\/\/doi.org\/10.1159\/000455280","journal-title":"Dev Ophthalmol."},{"issue":"5","key":"503_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/01.iae.0000249577.92800.c0","volume":"27","author":"JK Schmier","year":"2007","unstructured":"Schmier JK, Halpern MT, Covert DW, Matthews GP (2007) Evaluation of costs for cystoid macular edema among patients after cataract surgery. Retina 27(5):621\u2013628. https:\/\/doi.org\/10.1097\/01.iae.0000249577.92800.c0","journal-title":"Retina"},{"key":"503_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2147\/OPTH.S98892","volume":"10","author":"JK Schmier","year":"2016","unstructured":"Schmier JK, Covert DW, Hulme-Lowe CK, Mullins A, Mahlis EM (2016) Treatment costs of cystoid macular edema among patients following cataract surgery. Clin Ophthalmol 10:477\u2013483. https:\/\/doi.org\/10.2147\/OPTH.S98892","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"503_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/ceo.13513","volume":"47","author":"JV Han","year":"2019","unstructured":"Han JV, Patel DV, Squirrell D, McGhee CN (2019) Cystoid macular oedema following cataract surgery: A review. Clin Exp Ophthalmol 2019 47(3):346\u2013356. https:\/\/doi.org\/10.1111\/ceo.13513","journal-title":"Clin Exp Ophthalmol 2019"},{"issue":"12","key":"503_CR7","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1080\/02713683.2021.1929330","volume":"46","author":"MR Starr","year":"2021","unstructured":"Starr MR, Cai L, Obeid A, Ryan EH, Eliott D, Ryan C, Forbes NJ, Ammar M, Patel LG, Capone A, Emerson GG, Joseph DP, Gupta OP, Regillo CD, Hsu J, Yonekawa Y, Primary Retinal Detachment Outcomes (PRO) Study Group (2021) Risk factors for presence of cystoid macular edema following rhegmatogenous retinal detachment surgery. Curr Eye Res 46(12):1867\u20131875. https:\/\/doi.org\/10.1080\/02713683.2021.1929330","journal-title":"Curr Eye Res"},{"issue":"1","key":"503_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40662-021-00252-4","volume":"8","author":"L Iuliano","year":"2021","unstructured":"Iuliano L, Cisa di Gresy G, Fogliato G, Corbelli E, Bandello F, Codenotti M (2021) Increased risk of postsurgical macular edema in high stage idiopathic epiretinal membranes. Eye Vis (Lond) 8(1):29. https:\/\/doi.org\/10.1186\/s40662-021-00252-4","journal-title":"Eye Vis (Lond)"},{"issue":"Suppl 1","key":"503_CR9","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1016\/s0039-6257(02)00294-1","volume":"47","author":"K Miyake","year":"2002","unstructured":"Miyake K, Ibaraki N (2002) Prostaglandins and cystoid macular edema. Surv Ophthalmol 47(Suppl 1):S203\u2013S218. https:\/\/doi.org\/10.1016\/s0039-6257(02)00294-1","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"503_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/IIO.0b013e3181c551da","volume":"50","author":"NR Benitah","year":"2010","unstructured":"Benitah NR, Arroyo JG (2010) Pseudophakic cystoid macular edema. Int Ophthalmol Clin 50(1):139\u2013153. https:\/\/doi.org\/10.1097\/IIO.0b013e3181c551da","journal-title":"Int Ophthalmol Clin"},{"key":"503_CR11","unstructured":"Summary of Product Characteristics: ILUVIEN 190 micrograms intravitreal implant in applicator. Available in:\u00a0https:\/\/www.medicines.org.uk\/emc\/product\/3061\/smpc#gref. Last Accessed 2 Nov 2024"},{"issue":"10","key":"503_CR12","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, ReichelE, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME Study Group","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, ReichelE, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME Study Group (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit forat least 3 years in patients with diabetic macular edema. Ophthalmology 119(10):2125\u201332. https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.030","journal-title":"Ophthalmology"},{"issue":"3","key":"503_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/ICB.0000000000000779","volume":"15","author":"SS Ong","year":"2021","unstructured":"Ong SS, Walter SD, Chen X, Thomas AS, Finn AP, Fekrat S (2021) Bilateral intravitreal 019-mg fluocinolone acetonide implantfor persistent nondiabetic cystoid macular edema after vitrectomy. Retin Cases Brief Rep 15(3):261\u2013265. https:\/\/doi.org\/10.1097\/ICB.0000000000000779","journal-title":"Retin Cases Brief Rep"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/IMCRJ.S295045","volume":"14","author":"JH Marques","year":"2021","unstructured":"Marques JH, Abreu AC, Silva N, Meireles A, Pessoa B, Melo Beir\u00e3o J (2021) Fluocinolone Acetonide 0.19 mg Implant inPatients with Cystoid Macular Edema Due To Irvine-Gass Syndrome. Int Med CaseRep J 14:127\u2013132. https:\/\/doi.org\/10.2147\/IMCRJ.S295045","journal-title":"Int Med CaseRep J"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"112067212211246","DOI":"10.1177\/11206721221124688","volume":"4","author":"A Chronopoulos","year":"2022","unstructured":"Chronopoulos A, Chronopoulos P, Hattenbach LO, Ashurov A, Schutz JS, Pfeiffer N, Korb C (2022) Intravitreal fluocinoloneacetonide implant for chronic postoperative cystoid macular edema - two yearsresults. Eur J Ophthalmol 4:11206721221124688. https:\/\/doi.org\/10.1177\/11206721221124688","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"503_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40123-022-00613-9","volume":"12","author":"M Lima-Fontes","year":"2023","unstructured":"Lima-Fontes M, Leuzinger-Dias M, Barros-PereiraR Fernandes V, Falc\u00e3o M, Falc\u00e3o-Reis F, Rocha-Sousa A, Alves-Faria P (2023) IntravitrealFluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN\u00ae) in theTreatment of Patients with Recurrent Cystoid Macular Edema After Pars PlanaVitrectomy. Ophthalmol Ther 12(1):377\u2013388. https:\/\/doi.org\/10.1007\/s40123-022-00613-9","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"503_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4274\/tjo.34966","volume":"48","author":"F Alfaqawi","year":"2018","unstructured":"Alfaqawi F, Sarmad A, Ayesh K, Mitra A, Sharma A (2018) Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatmentof Refractory Cystoid Macular Oedema After Retinal Detachment Repair. Turk JOphthalmol 48(3):155\u2013157. https:\/\/doi.org\/10.4274\/tjo.34966","journal-title":"Turk JOphthalmol"},{"issue":"1","key":"503_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40123-020-00232-2","volume":"9","author":"TR Herold","year":"2020","unstructured":"Herold TR, Liegl R, Koenig S, Almarzooqi A, Priglinger SG, Wolf A (2020) Scleral Fixation of the Fluocinolone AcetonideImplant in Eyes with Severe Iris-Lens Diaphragm Disruption and RecalcitrantCME: The Fluocinolone-Loop-Anchoring Technique (FLAT). Ophthalmol Ther 9(1):175\u2013179. https:\/\/doi.org\/10.1007\/s40123-020-00232-2","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"503_CR19","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1097\/IAE.0000000000003472","volume":"42","author":"TR Herold","year":"2022","unstructured":"Herold TR, Vounotrypidis E, Liegl R, Koenig SF, Priglinger SG, Wolf A (2022) Long-term efficacy of fluocinolone in eyes withiris-lens diaphragm disruption and PCME with medication fixed in the sclera(mefisto). Retina 42(7):1392\u20131398. https:\/\/doi.org\/10.1097\/IAE.0000000000003472","journal-title":"Retina"},{"issue":"1","key":"503_CR20","doi-asserted-by":"publisher","first-page":"NP23","DOI":"10.1177\/11206721211046718","volume":"33","author":"L Miguel-Escuder","year":"2023","unstructured":"Miguel-Escuder L, Olate-P\u00e9rez \u00c1, Sala-PuigdonersA Moll-Udina A, Figueras-Roca M, Navarro-Angulo MJ, Ad\u00e1n A, Pelegr\u00edn L (2023) Intravitreal fluocinolone acetonide implant for the treatment ofpersistent post-surgical cystoid macular edema in vitrectomized eyes. Eur JOphthalmol 33(1):NP23\u2013NP27. https:\/\/doi.org\/10.1177\/11206721211046718","journal-title":"Eur JOphthalmol"},{"key":"503_CR21","doi-asserted-by":"publisher","unstructured":"Kiernan DF (2023) Sustained-release Low-doseFluocinolone Acetonide Intravitreal Implant for Chronic Postoperative CystoidMacular Edema: Two Case Reports. Retin Cases Brief Rep. https:\/\/doi.org\/10.1097\/ICB.0000000000001404","DOI":"10.1097\/ICB.0000000000001404"},{"issue":"6","key":"503_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/IAE.0000000000003765","volume":"43","author":"JD Deaner","year":"2023","unstructured":"Deaner JD, Mammo D, Gross A, Lee T, Sharma S, Srivastava SK, Jaffe GJ, Grewal DS (2023) 0.18 mg fluocinolone acetonide insert for the treatment of chronic postoperative pseudophakic cystoid macular edema. Retina 43(6):897\u2013904. https:\/\/doi.org\/10.1097\/IAE.0000000000003765","journal-title":"Retina."},{"issue":"10","key":"503_CR23","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1097\/IAE.0000000000003855","volume":"43","author":"KG Patel","year":"2023","unstructured":"Patel KG, Flores J, Abbey AM (2023) Injectablefluocinolone implant for the management of chronic postsurgical cystoid macularedema in vitrectomized eyes. Retina 43(10):1732\u20131737. https:\/\/doi.org\/10.1097\/IAE.0000000000003855","journal-title":"Retina"},{"issue":"24","key":"503_CR24","doi-asserted-by":"publisher","first-page":"00327","DOI":"10.1016\/j.oret.2024.07.004","volume":"S2468-6530","author":"K Motloch","year":"2024","unstructured":"Motloch K, Soler V, Delyfer MN, Vasseur V, WolffB Issa M, Dot C, Mass\u00e9 H, Weber M, Comet A, Hitzl W, Matonti F, Creuzot-Garcher C, Tadayoni R, Kodjikian L, Couturier A (2024) Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy: The ILUvien in Postoperative\u00a0CYstoid Macular eDema study. Ophthalmol Retina S2468-6530(24):00327\u20130. https:\/\/doi.org\/10.1016\/j.oret.2024.07.004","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"503_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40942-020-00254-9","volume":"7","author":"C Pole","year":"2021","unstructured":"Pole C, Chehaibou I, Govetto A, Garrity S, Schwartz SD, Hubschman JP (2021) Macular edema after rhegmatogenous retinaldetachment repair: risk factors, OCT analysis, and treatment responses. Int JRetina Vitreous 7(1):9. https:\/\/doi.org\/10.1186\/s40942-020-00254-9","journal-title":"Int JRetina Vitreous"},{"issue":"4","key":"503_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","volume":"110","author":"PM Beer","year":"2003","unstructured":"Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M (2003) Intraocular concentration and pharmacokinetics oftriamcinolone acetonide after a single intravitreal injection. Ophthalmology 110(4):681\u20136. https:\/\/doi.org\/10.1016\/S0161-6420(02)01969-3","journal-title":"Ophthalmology"},{"issue":"12","key":"503_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/17425255.2017.1404987","volume":"13","author":"M Edington","year":"2017","unstructured":"Edington M, Connolly J, Chong NV (2017) Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versusnon-vitrectomized eyes. Expert Opin Drug Metab Toxicol 13(12):1217\u20131224. https:\/\/doi.org\/10.1080\/17425255.2017.1404987","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"503_CR28","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1167\/iovs.10-6387","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Burke JA, Peng Q, Lin T, OrillaWC Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF (2011) Pharmacokinetics of a sustained-release dexamethasone intravitreal implant invitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 52(7):4605\u20139. https:\/\/doi.org\/10.1167\/iovs.10-6387","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"503_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00347-016-0223-y","volume":"113","author":"LO Hattenbach","year":"2016","unstructured":"Hattenbach LO, Kuhli-Hattenbach C, Springer C, Callizo J, Hoerauf H (2016) Intravitreal dexamethasone implant for treatment ofpersistent postoperative macular edema after vitrectomy. Ophthalmologe 113(7):581\u20138. https:\/\/doi.org\/10.1007\/s00347-016-0223-y","journal-title":"Ophthalmologe"},{"issue":"4","key":"503_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000448057","volume":"236","author":"A Klamann","year":"2016","unstructured":"Klamann A, B\u00f6ttcher K, Ackermann P, Geerling G, SchargusM Guthoff R (2016) Intravitreal Dexamethasone Implant for the Treatment ofPostoperative Macular Edema. Ophthalmologica 236(4):181\u2013185. https:\/\/doi.org\/10.1159\/000448057","journal-title":"Ophthalmologica"},{"key":"503_CR31","doi-asserted-by":"publisher","first-page":"3946531","DOI":"10.1155\/2020\/3946531","volume":"2020","author":"S Freissinger","year":"2020","unstructured":"Freissinger S, Vounotrypidis E, Wolf A, KortuemKU Shajari M, Sakkias F, Herold T, Priglinger SG, Mayer WJ (2020) Evaluation of Functional Outcomes and OCT-Biomarkers after IntravitrealDexamethasone Implant for Postoperative Cystoid Macular Edema in VitrectomizedEyes. J Ophthalmol 2020:3946531. https:\/\/doi.org\/10.1155\/2020\/3946531","journal-title":"J Ophthalmol"},{"issue":"3","key":"503_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/bjophthalmol-2016-308544","volume":"101","author":"D Bellocq","year":"2017","unstructured":"Bellocq D, Pierre-Kahn V, Matonti F, Burillon C, Voirin N, Dot C, Akesbi J, Milazzo S, Baillif S, Soler V, Wolff B, ScemamaC Malcl\u00e8s A, Weber M, Kodjikian L (2017) Effectiveness and safety ofdexamethasone implants for postsurgical macular oedema including Irvine-Gasssyndrome: the EPISODIC-2 study. Br J Ophthalmol 101(3):333\u2013341. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308544","journal-title":"Br J Ophthalmol"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00503-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00503-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00503-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T01:43:40Z","timestamp":1755308620000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-025-00503-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00503-8","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case series adheres to the guidelines for human studies and was conducted ethically in accordance with the principles outlined in the Declaration of Helsinkiand all applicable country-specific regulations governing the conduct of clinical research, depending on which provided greater protection to the individual. Any potentially identifying information has been encrypted or omitted, as necessary, to ensure the anonymity of individuals involved in the study. Ethical approval for this study was obtained from the Local Institutional Review Board [approval number\/2025-91]. Due to the characteristics of this study, informed consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Maria Filipa Madeira: Payment of fees for open access publication: Alimera Sciences. Ana Cabugueira: Payment of fees for open access publication: Alimera Sciences. Helena Urbano: Payment of fees for open access publication: Alimera Sciences. Miguel Cordeiro: Payment of fees for open access publication: Alimera Sciences. Marta Guedes: Payment of fees for open access publication: Alimera Sciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}